Announcements Trials
Browse Landscape

Phase

Phase NA 16Phase 2 12Phase 1 8Phase 1/2 6Phase EARLY_PHASE1 4Phase 3 3Phase 4 2Phase 2/3 2

Status

Not yet recruiting 1Enrolling by invitation 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Breast Neoplasms 27Neoplasms 10Carcinoma, Non-Small-Cell Lung 9Prostatic Neoplasms 7Multiple Myeloma 7Lung Neoplasms 7Melanoma 6Stomach Neoplasms 5Neoplasm Metastasis 4Leukemia, Myeloid, Acute 4Glioma 4Colorectal Neoplasms 4Carcinoma, Hepatocellular 4Tuberous Sclerosis 3Sarcoma 3Papillomavirus Infections 3Ovarian Neoplasms 3Hematologic Neoplasms 3Glioblastoma 3Warts 2Venous Thromboembolism 2Thyroid Neoplasms 2Skin Neoplasms 2Rectal Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Polycythemia Vera 2Oligodendroglioma 2Obesity 2Neoplasms by Site 2Myasthenia Gravis 2

Interventions

relatlimab 1oxycodone-acetaminophen 1Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 4 × Skin Neoplasms × 90 days × Clear all
NCT07575230 2026-05-11

Suzetrigine vs Norco-postoperative Mohs Pain

Baylor Research Institute

Phase 4 Enrolling by invitation
75 enrolled
Dermatologic

Skin Neoplasms

NCT07459543 2026-03-09

A Study To Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Untreated, Unresectable or Metastatic Melanoma Participants In India

Bristol-Myers Squibb

Phase 4 Not yet recruiting
30 enrolled
Dermatologic

Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡